Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
The personalized approach, though promising, faces skepticism due to the high cost and difficulty of scaling production.BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic.
BioNTech（biontech）股份有限公司（納斯達克代碼：BNTX）和Moderna（moderna）股份有限公司（納斯達克代碼：MRNA）在個人化癌症疫苗方面取得了進展，利用了COVID-19大流行期間的mRNA技術。
Also Read: FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot.
此外，FDA批准了輝瑞和Moderna的更新版COVID疫苗，但卻沒有包括諾瓦瓦克斯醫藥的產品。
These companies, whose stocks plummeted by about 80% since their 2021 pandemic peaks, are now focusing on cancer treatments to revive their fortunes.
這些公司的股票自2021年大流行的高峰以來暴跌約80%，現在它們正在聚焦於癌症治療以重振其命運。
The personalized approach, though promising, faces skepticism due to the high cost and difficulty of scaling production.
儘管個人化方法前景看好，但由於高昂的成本和生產規模的困難，它面臨着懷疑。
Miranda Payne, a melanoma specialist leading a Moderna trial at Oxford's Churchill Hospital, expressed excitement about the potential but noted the challenges in making these vaccines widely available.
牛津大學丘吉爾醫院的黑素瘤專家Miranda Payne在領導一項Moderna試驗時表達了對潛力的興奮，但同時指出了普遍供應這些疫苗的挑戰。
The Financial Times notes the high cost of sequencing each patient's tumor and producing bespoke vaccines raises concerns about the feasibility of widespread application.
《金融時報》注意到每個患者的腫瘤測序和定製疫苗的高成本引發了對廣泛應用可行性的擔憂。
Moderna's melanoma vaccine, developed in partnership with Merck & Co Inc (NYSE:MRK), is in advanced trials, while BioNTech's product, co-developed with Roche Holdings AG's (OTC:RHHBY) subsidiary Genentech, is being tested in an NHS trial.
Moderna與Merck＆Co Inc（紐約證券交易所：MRK）合作開發的黑色素瘤疫苗正在進行高級試驗，而BioNTech與Roche Holdings AG（場外交易：RHHBY）旗下的Genentech合作開發的產品正在進行NHS試驗中。
Also Read: Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients.
此外還有：Moderna和Merck公佈了高風險黑素瘤患者個體化癌症治療三年數據。
Despite the optimism, experts caution that while the individual approach is exciting, the high costs and challenges of production make it uncertain whether these personalized vaccines will be scalable or affordable.
儘管樂觀，但專家們警告說，儘管個體化方法令人興奮，但高昂的成本和生產挑戰使得這些個性化疫苗能否具有可擴展性或可負擔性成爲不確定因素。
Uğur Şahin, CEO of BioNTech, emphasized the importance of innovation in personalizing mRNA vaccines, predicting that these treatments could be as impactful as existing immunotherapies by 2030.
BioNTech的首席執行官Uğur Şahin強調了個性化mRNA疫苗創新的重要性，並預測到2030年，這些治療可能會像現有的免疫治療方法一樣具有影響力。
Moderna is likely to bring its cancer vaccine to market first, focusing on lung and skin cancers. The company is also investing in new manufacturing facilities to improve production efficiency. BioNTech is taking a dual approach, developing personalized and off-the-shelf vaccines to address different cancer types.
Moderna很可能率先將其癌症疫苗引入市場，重點放在肺癌和皮膚癌上。該公司還在投資新的製造設施，以提高生產效率。BioNTech採取雙重方法，開發個體化和現成的疫苗以應對不同的癌症類型。
As BioNTech and Moderna push forward, the cancer treatment landscape could be transformed, but the journey is fraught with obstacles.
隨着BioNTech和Moderna的推進，癌症治療前景可能會發生變化，但這個過程充滿了許多困難。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside.
- Bullish Analyst認爲，NewAmsterdam Pharma的降低膽固醇藥物銷量將巨大增長。